

**COURTESY COPY OF THE
INTERNATIONAL
PRELIMINARY EXAMINATION
REPORT WITH ANNEXES
CONTAINING CLAIMS 1-19 TO BE
SUBSTITUTED FOR ORIGINAL
CLAIMS 1-23 FOR
EXAMINATION IN THIS CASE**

Claims

1. IgY that originates from an egg of a bird hyperimmunised with a microbe for use in prophylaxis or treatment of enteric infection in newborn infants, prematurely born infants, infants having an immature immune system, patients suffering from temporary immunodeficiency and immunodeficiency diseases such as AIDS.
2. IgY according to claim 1, wherein the microbe is a bacterium, virus, fungus or parasite.
3. IgY according to any of the preceding claims, wherein the infection is a bacterial infection.
4. IgY according to any of the preceding claims, wherein the infection is an intestinal infection.
5. IgY according to any of the preceding claims, wherein the infection is an intestinal bacterial infection
6. IgY according to any of the preceding claims, wherein the microbe is Enterobacter cloacae.
7. IgY according to any of the preceding claims, wherein the microbe is Candida albicans.
8. Pharmaceutical composition, comprising the IgY according to any of the claims 1-7, wherein the IgY is formulated as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as a capsule together with any other pharmaceutically acceptable carrier or diluent.
9. Pharmaceutical composition according to claim 8, further comprising a nutritional agent.

REPLACED BY
ART 34 AMDT

10. Pharmaceutical composition according to claim 9, wherein the nutritional agent is human breast milk or a substitute therefore.
11. Method of prophylaxis or treatment of enteric infections in newborn infants,
5 prematurely born infants, infants having an immature immune system, patients suffering from temporary immunodeficiency and immunodeficiency diseases such as AIDS, comprising the step of:
administering to said infant or patient a composition comprising IgY that originates from an egg of a bird hyperimmunised with a microbe.
- 10 12. Method according to claim 11, wherein the microbe is a bacterium, virus, fungus or parasite.
13. Method according to claim 11, wherein the infection is a bacterial infection.
- 15 14. Method according to claim 11, wherein the microbe is *Enterobacter cloacae*.
15. Method according to claim 11, further comprising formulating the composition as a freeze dried or lyophilised powder, a solution, an emulsion, a lozenge, a tablet or as
20 a capsule or administering it together with any other pharmaceutically acceptable carrier or diluent.
16. Method according to claim 11, wherein the composition is administered together with a nutritional agent.
- 25 17. Method according to claim 16, wherein the nutritional agent is human breast milk or a substitute therefore.
18. Method according to claim 11, wherein the composition is administered to newborn
30 infants having an immature immune system.
19. Method according to claim 11, wherein the composition is administered to newborn infants having a weight below 2500g.

REPLACED BY
ART 34 AMDT

20. Method according to claim 11, wherein the composition is administered to prematurely born infants.
- 5 21. Method according to claim 11, wherein the composition is administered to newborn infants having a pH above 1,5.
22. Method according to claim 11, wherein the composition is administered to newborn infants having pH between 1,5 and 4.
- 10 23. Use of IgY that originates from an egg of a bird hyperimmunised with a microbe for the manufacture of a pharmaceutical medicament for use in prophylaxis or treatment of enteric infection in newborn infants, prematurely born infants, infants having an immature immune system, patients suffering from temporary
- 15 immunodeficiency and immunodeficiency diseases such as AIDS.